A NYT article has Wall Street abuzz today with whispers of non-profit hospital groups creating a new generics maker or partnering with third party manufacturers.
Cantor’s Louise Chen dismisses Valeant share weakness today, making a bullish case that the majority of Xifaxan’s sales stem from IBS-D; not Traveler’s Diarrhea.
In reaction to acquisition buzz in the market’s grapevine, Maxim’s Jason McCarthy is out boosting his price target on Juno stock.
BTIG’s Tim Chiang notes that with various positives soaring in Valeant’s favor, these are mostly reflected in the stock’s recently climbing levels.
The company’s future is in serious doubt, but it doesn’t prevent Oppenheimer’s Jay Olson from hitting the ‘buy’ button.
Guggenheim’s Rohit Vanjani reacts to the debt rating downgrade on Teva from the sidelines without shock, having seen the writing on the wall.